Literature DB >> 22339537

GSTO and AS3MT genetic polymorphisms and differences in urinary arsenic concentrations among residents in Bangladesh.

Ema G Rodrigues1, Molly Kile, Elaine Hoffman, Quazi Quamruzzaman, Mahmuder Rahman, Golam Mahiuddin, Yumei Hsueh, David C Christiani.   

Abstract

We determined whether single nucleotide polymorphisms (SNPs) in the glutathione S-transferase omega (GSTO) and arsenic(III)methyltransferase (AS3MT) genes were associated with concentrations of urinary arsenic metabolites among 900 individuals without skin lesions in Bangladesh. Four SNPs were assessed in these genes. A pathway analysis evaluated the association between urinary arsenic metabolites and SNPs. GSTO1 rs4925 homozygous wild type was significantly associated with higher monomethylarsonic acid (MMA) and dimethylarsinic acid urinary concentrations, whereas wild-type AS3MT rs11191439 had significantly lower levels of As(III) and MMA. Genetic polymorphisms GSTO and As3MT modify arsenic metabolism as evidenced by altered urinary arsenic excretion.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22339537      PMCID： PMC3340466          DOI： 10.3109/1354750X.2012.658863

Source DB:  PubMed          Journal:  Biomarkers        ISSN： 1354-750X            Impact factor:   2.658


  28 in total

1.  Arsenic methylation capacity and skin cancer.

Authors:  R C Yu; K H Hsu; C J Chen; J R Froines
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-11       Impact factor: 4.254

2.  Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells.

Authors:  M Styblo; L M Del Razo; L Vega; D R Germolec; E L LeCluyse; G A Hamilton; W Reed; C Wang; W R Cullen; D J Thomas
Journal:  Arch Toxicol       Date:  2000-08       Impact factor: 5.153

3.  Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina.

Authors:  Craig Steinmaus; Yan Yuan; Dave Kalman; Omar A Rey; Christine F Skibola; Dave Dauphine; Anamika Basu; Kristin E Porter; Alan Hubbard; Michael N Bates; Martyn T Smith; Allan H Smith
Journal:  Toxicol Appl Pharmacol       Date:  2010-06-17       Impact factor: 4.219

4.  Enzymatic reduction of arsenic compounds in mammalian systems: the rate-limiting enzyme of rabbit liver arsenic biotransformation is MMA(V) reductase.

Authors:  R A Zakharyan; H V Aposhian
Journal:  Chem Res Toxicol       Date:  1999-12       Impact factor: 3.739

5.  Asian specific low mutation frequencies of the M287T polymorphism in the human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene.

Authors:  Junko Fujihara; Mikiko Soejima; Yoshiro Koda; Takashi Kunito; Haruo Takeshita
Journal:  Mutat Res       Date:  2008-06-07       Impact factor: 2.433

6.  Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile.

Authors:  Alba Hernández; Noel Xamena; Jordi Surrallés; Chandra Sekaran; Hiroshi Tokunaga; Domingo Quinteros; Amadeu Creus; Ricardo Marcos
Journal:  Mutat Res       Date:  2007-07-22       Impact factor: 2.433

7.  Gender and age differences in the metabolism of inorganic arsenic in a highly exposed population in Bangladesh.

Authors:  Anna-Lena Lindberg; Eva-Charlotte Ekström; Barbro Nermell; Mahfuzar Rahman; Bo Lönnerdal; Lars-Ake Persson; Marie Vahter
Journal:  Environ Res       Date:  2007-09-27       Impact factor: 6.498

Review 8.  A review on environmental factors regulating arsenic methylation in humans.

Authors:  Chin-Hsiao Tseng
Journal:  Toxicol Appl Pharmacol       Date:  2008-12-30       Impact factor: 4.219

9.  Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies.

Authors:  Santiago Rodriguez; Tom R Gaunt; Ian N M Day
Journal:  Am J Epidemiol       Date:  2009-01-06       Impact factor: 4.897

10.  Variability in biomarkers of arsenic exposure and metabolism in adults over time.

Authors:  Molly L Kile; Elaine Hoffman; Yu-Mei Hsueh; Sakila Afroz; Quazi Quamruzzaman; Mahmuder Rahman; Golam Mahiuddin; Louise Ryan; David C Christiani
Journal:  Environ Health Perspect       Date:  2008-11-19       Impact factor: 9.031
View more
  18 in total

1.  Association between polymorphisms in arsenic metabolism genes and urinary arsenic methylation profiles in girls and boys chronically exposed to arsenic.

Authors:  Rogelio Recio-Vega; Tania González-Cortes; Edgar Olivas-Calderón; R Clark Lantz; A Jay Gandolfi; Gladis Michel-Ramirez
Journal:  Environ Mol Mutagen       Date:  2016-06-21       Impact factor: 3.216

2.  A human-specific AS3MT isoform and BORCS7 are molecular risk factors in the 10q24.32 schizophrenia-associated locus.

Authors:  Ming Li; Andrew E Jaffe; Richard E Straub; Ran Tao; Joo Heon Shin; Yanhong Wang; Qiang Chen; Chao Li; Yankai Jia; Kazutaka Ohi; Brady J Maher; Nicholas J Brandon; Alan Cross; Joshua G Chenoweth; Daniel J Hoeppner; Huijun Wei; Thomas M Hyde; Ronald McKay; Joel E Kleinman; Daniel R Weinberger
Journal:  Nat Med       Date:  2016-05-09       Impact factor: 53.440

3.  Polymorphisms in maternal folate pathway genes interact with arsenic in drinking water to influence risk of myelomeningocele.

Authors:  Maitreyi Mazumdar; Linda Valeri; Ema G Rodrigues; Md Omar Sharif Ibne Hasan; Rezina Hamid; Ligi Paul; Jacob Selhub; Fareesa Silva; Md Golam Mostofa; Quazi Quamruzzaman; Mahmuder Rahman; David C Christiani
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2015-08-06

4.  Influence of GSTT1 Genetic Polymorphisms on Arsenic Metabolism.

Authors:  Molly L Kile; E Andres Houseman; Quazi Quamruzzaman; Mahmuder Rahman; Golam Mahiuddin; Golam Mostofa; Yu-Mei Hsueh; David C Christiani
Journal:  J Indian Soc Agric Stat       Date:  2013-08-01

5.  Differential metabolism of inorganic arsenic in mice from genetically diverse Collaborative Cross strains.

Authors:  Miroslav Stýblo; Christelle Douillet; Jacqueline Bangma; Lauren A Eaves; Fernando Pardo-Manuel de Villena; Rebecca Fry
Journal:  Arch Toxicol       Date:  2019-09-06       Impact factor: 5.153

6.  Interaction between arsenic exposure from drinking water and genetic susceptibility in carotid intima-media thickness in Bangladesh.

Authors:  Fen Wu; Farzana Jasmine; Muhammad G Kibriya; Mengling Liu; Xin Cheng; Faruque Parvez; Rachelle Paul-Brutus; Rina Rani Paul; Golam Sarwar; Alauddin Ahmed; Jieying Jiang; Tariqul Islam; Vesna Slavkovich; Tatjana Rundek; Ryan T Demmer; Moise Desvarieux; Habibul Ahsan; Yu Chen
Journal:  Toxicol Appl Pharmacol       Date:  2014-03-02       Impact factor: 4.219

7.  Determinants and Consequences of Arsenic Metabolism Efficiency among 4,794 Individuals: Demographics, Lifestyle, Genetics, and Toxicity.

Authors:  Rick J Jansen; Maria Argos; Lin Tong; Jiabei Li; Muhammad Rakibuz-Zaman; Md Tariqul Islam; Vesna Slavkovich; Alauddin Ahmed; Ana Navas-Acien; Faruque Parvez; Yu Chen; Mary V Gamble; Joseph H Graziano; Brandon L Pierce; Habibul Ahsan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-16       Impact factor: 4.254

8.  Gut microbiome perturbations induced by bacterial infection affect arsenic biotransformation.

Authors:  Kun Lu; Peter Hans Cable; Ryan Phillip Abo; Hongyu Ru; Michelle E Graffam; Katherine Ann Schlieper; Nicola M A Parry; Stuart Levine; Wanda M Bodnar; John S Wishnok; Miroslav Styblo; James A Swenberg; James G Fox; Steven R Tannenbaum
Journal:  Chem Res Toxicol       Date:  2013-11-18       Impact factor: 3.739

9.  Mendelian randomization analysis of arsenic metabolism and pulmonary function within the Hispanic Community Health Study/Study of Latinos.

Authors:  Molly Scannell Bryan; Tamar Sofer; Majid Afshar; Yasmin Mossavar-Rahmani; H Dean Hosgood; Naresh M Punjabi; Donglin Zeng; Martha L Daviglus; Maria Argos
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

Review 10.  In vivo and in vitro methods for evaluating soil arsenic bioavailability: relevant to human health risk assessment.

Authors:  Karen D Bradham; Gary L Diamond; Michele Burgess; Albert Juhasz; Julie M Klotzbach; Mark Maddaloni; Clay Nelson; Kirk Scheckel; Sophia M Serda; Marc Stifelman; David J Thomas
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2018       Impact factor: 8.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.